Novel Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion-Selective Inhibitors for Lung Cancer Therapy

ACS Medicinal Chemistry Letters 2026 Open access

Read full text
Authors: Yanwei Jiang, Steven H. Liang
DOI: 10.1021/acsmedchemlett.6c00030
Cited by: 0
References: 8

Abstract

This patent describes novel prop-2-ynamide-derived epidermal growth factor receptor (EGFR) inhibitors, which selectively target EGFR exon20 insertion mutations. These EGFR inhibitors exhibit therapeutic potential for the treatment of nonsmall cell lung cancer (NSCLC) and other malignancies driven by EGFR mutations.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Synthesis and biological activity

Publication details

Journal / source
ACS Medicinal Chemistry Letters
Volume
17
Issue
3
Pages
611–612
Publication date
9 February 2026
Language
EN